E
Elena Santagostino
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 323
Citations - 12601
Elena Santagostino is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 54, co-authored 320 publications receiving 10601 citations. Previous affiliations of Elena Santagostino include University of Milan.
Papers
More filters
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg,Johnny Mahlangu,Benjamin Kim,Christophe Schmitt,Michael U. Callaghan,Guy Young,Elena Santagostino,Rebecca Kruse-Jarres,Claude Negrier,Craig M. Kessler,Nancy Valente,Elina Asikanius,Gallia G. Levy,Jerzy Windyga,Midori Shima +14 more
TL;DR: Empicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no proPHylaxis among participants with hemophilia A with inhibitors and resulted in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing‐agent prophylum.
Journal ArticleDOI
The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.
Raed Al Dieri,Flora Peyvandi,Elena Santagostino,Muriel Giansily,Pier Mannuccio Mannucci,Jean François Schved,Suzette Beguin,H. Coenraad Hemker +7 more
TL;DR: This value corroborates the clinical observation that a severe bleeding tendency is only seen in severe clotting factor deficiencies (less than 1%), and the one exception was a patient with factor VII deficiency and severe bleeding, who showed a normal ETP value, albeit with a decreased peak height and a prolonged lag-time.
Journal ArticleDOI
International workshop on immune tolerance induction: consensus recommendations
TL;DR: An international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophiles and these recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.
Journal ArticleDOI
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
Alfonso Iorio,Susan Halimeh,Susanne Holzhauer,Neil A. Goldenberg,Emanuela Marchesini,Maura Marcucci,Guy Young,Christoph Bidlingmaier,Leonardo R. Brandão,C. E. Ettingshausen,Alessandro Gringeri,Gili Kenet,Ralf Knöfler,Wolfhart Kreuz,Karin Kurnik,Daniela Manner,Elena Santagostino,P. M. Mannucci,Ulrike Nowak-Göttl +18 more
TL;DR: The need for randomized controlled trials to address whether or not the risk of inhibitor in PUPs with hemophilia A differs between rFV III and pdFVIII is underscored.